Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systemsproducts and services

Cypex - in vitro drug metabolism systemsabout us

Cypex - in vitro drug metabolism systemslatest news

Cypex - in vitro drug metabolism systemsdata sheets
Cypex - in vitro drug metabolism systemspublications
Cypex - in vitro drug metabolism systemsfrequently asked questions
Cypex - in vitro drug metabolism systemsassays
Cypex - in vitro drug metabolism systemscontact us
linksCypex - in vitro drug metabolism systems
Cypex - in vitro drug metabolism systems
Follow us:   RSS Feed icon   LinkedIn logo
bio-dundee logoscottish enterprise biotech
products and services
 

Inhibition Screening:

Cypex has introduced fluorimetry based assays to determine the CYP inhibition potential of novel compounds, using Bactosomes as the enzyme source.

Download pdf information brochure here

  • NEW Now 8 major CYPs covered (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5).
  • CYP activity determined at 8 different compound concentrations and fitted to a model using XLfit® software, before determining an IC50 value.
  • 30 minute incubation time - shifts in IC50 value over time can indicate whether the compound has the potential to be a time dependent inhibitor of each CYP isoform.
  • Positive control inhibitor and multi well negative control is run in parallel on every plate, giving confidence in the end result.
  • Recommended solvents are DMSO and methanol up to 2.5% (v/v), assuming compound solubility.
  • Cost effective and fast turnaround of data after receipt of compound.












Screening Publications

Development of a fluorimetric assay for determining IC50 values with Bactosomes for 8 major human CYP isoforms; incorporation of IC50 value changes as a function of time to predict time/metabolism dependent inhibition.
(Downloadable as a pdf)

Effect of solvent choice when performing fluorimetric IC50 assays with Bactosomes can influence the end result.
(Downloadable as a pdf)


Development of a fluorimetric assay to identify inhibitors of recombinant CYP2B6.
(Downloadable as a pdf)


Contact us for more information

Important: By purchasing these products from Cypex you accept the standard terms and conditions of supply, details of which are freely available on request.

The following are made under licence from BTG International Ltd (AU730155, EP0914446, US6566108 and other patents pending): all recombinant cytochrome P450 products; 4'-hydroxydiclofenac; 6alpha-hydroxypaclitaxel.

United States Patent Nos. 5,420,027 or 5,240,831, Canada Patent No. 2100245 and other patents pending.

PRODUCTS & SERVICES | ABOUT US | LATEST NEWS | DATA SHEETS | PUBLICATIONS | FAQ'S | ASSAYS | CONTACT US | LINKS | INTRO | TERMS | HOME
Designed and created by Rob Cook at Limehouse Design